Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-06-17T09:25:36.692Z Has data issue: false hasContentIssue false
  • English
  • Français

A Randomized and Double- blind Clinical Trial of Venlafaxine Hydrochloride Sustained Release Capsules for Treating Juvenile Depression

Published online by Cambridge University Press:  16 April 2020

C. Hongfen ,
J. Weidong ,
Z. Guoquan ,
Y. Chuang  and
G. Tianyou
C. Hongfen
Affiliation:
Psychiatry, Shanghai Changning Mental Health Center/Bio-X Center Hospital of Shanghai Jiaotong University, Shanghai, China
J. Weidong
Affiliation:
Psychiatry, Shanghai Changning Mental Health Center/Bio-X Center Hospital of Shanghai Jiaotong University, Shanghai, China
Z. Guoquan
Affiliation:
Psychiatry, Shanghai Changning Mental Health Center/Bio-X Center Hospital of Shanghai Jiaotong University, Shanghai, China
Y. Chuang
Affiliation:
Psychiatry, Wenzhou Medical Collage, Wenzhou, China
G. Tianyou
Affiliation:
Psychology, Shenzhen University, Shenzhen, China

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Object:

To evaluate the efficacy and safety of venlafaxine hydrochloride(HCL) sustained release capsules in treating juvenile with depressive disorder.

Methods:

A randomized, double blind dummy clinical trial enrolled 60 adolescent patients with depression, who were randomizedly designed to administer venlafaxine HCL sustained release capsules 150 mg or fluoxetine 20 mg daily for 8 weeks. The efficacies of both treatment groups was evaluated based on the Hamilton Depression Scale and Clinical General impression Scale pre and post-treatment.

Results:

The scores of Hamilton Depression Scale at the end of therapy were significantly reduced compared with the baseline in both gtnups (P< 0.O1). The effective rate of venlafaxine HCL sustained release capsules versus fluoxetine treatmlent was 70.0% and 65.5%, respectively, the P value showed no statistical difference (P>0. OS). The common adverse reactions included dry mouth, insomnia, dizziness, and loss of appetite.

Conclusion:

Venlafaxine HCl sustained release capsules is an effective agent for juvenile with major depression.

Type
P01-114
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E502
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.